Clinical effect of combination therapy of pioglitazone and an α-glucosidase inhibitor

Abstract

SUMMARYThis study evaluated the efficacy of adding pioglitazone 30 mg to the therapy of patients with type 2 diabetes mellitus whose glycaemic control was poor on an α-glucosidase inhibitor (α-GI) alone or in combination with a sulphonylurea (SU).The patients (n = 20) had a HbA1c level between 7.0 and 12.0% and the fasting plasma glucose was 7.8 mmol l−1 or higher. They were treated with 30 mg pioglitazone once daily for 16 weeks.The decrease in HbA1c at week 16 of treatment was 0.8% (7.8% at baseline dropping to 7.1% at week 16; p < 0.01). An increase in leptin was observed 4 weeks after starting the post-study period (p < 0.05). Tumour necrosis factor-α (TNF-α) and body fat percentage did not show anysignificant alterations. Correlations between the decrease in HbA1c at week 16 and characteristic variables of patients were examined. A correlation with leptin (p = −0.5632, p < 0.05) levels was found. Five patients experienced adverse drug reactions, such as oedema, hypoglycaemia and increased creatine phosphokinase (CK), all of which were mild in severity.The addition of pioglitazone in diabetics whose glycaemic control was poor on a α-GI alone or with a α-GI and SU combination resulted in a significant decrease in HbA1c, and the treatment was well-tolerated. Our findings also suggest that leptin levels could be useful for assessing responders to pioglitazone.